New aspects of non-invasive diagnosis of intestinal pathology.

Автор(и)

  • N. S. Fedorova

DOI:

https://doi.org/10.26641/2307-0404.2018.1(part2).126948

Ключові слова:

inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, differential diagnosis, fecal calprotectin

Анотація

A comparative assessment of fecal calprotectin (FC) levels was performed in 160 patients with chronic inflammatory bowel disease (CIBD) (Crohn's disease (CD), ulcerative colitis (UC)) and irritable bowel syndrome (IBS). The results of FC in patients with CIBD and IBS were compared with the values of FC  of 31 healthy patients (control group). The mean FC level in pa­tients with CIBD was 65.75 μg/g compared to the control group (13.72 μg/g) (p<0.05). In the group of patients with IBS, the FC level was 16.18 μg/g (p≥0.05). Significant correlation was found between the levels of FC with CIBD and FC with IBS (p<0.05). The obtained results confirmed the high diagnostic value of the method of determining fecal calprotectin in the differential diagnosis of functional and inflammatory bowel diseases.

Біографія автора

N. S. Fedorova

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Family Medicine of FPE
V. Vernadsky str., 9, Dnipro, 49044, Ukraine

Посилання

Stepanov JuM,FedorovaNS. [The comparative content of fecal calprotectin in patients with chronic in­flam­matory bowel diseases and functional pathology of the colon]. Dnіpropetrovsk, Gastroenterologіya. 2010;401-6. Russian.

Stepanov JuM,FedorovaNS. [Realities and per­spectives in the diagnosis of bowel diseases]. Suchasna gastroenterologіya. 2010;1(51):109-13. Russian.

FedorovaNS, Khanyukov AA. [Opportunities and prospects in the diagnosis of functional bowel di­sease]. Zdorov'e rebenka. 2017;12(2.1). Russian.

Carroccio A, Jacono G, Cottone М. Diagnostic Accuracy of Fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clinical Chemistry. 2003;49:861-7.

Longstresh GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.

Lorens-Meyer H. Inflammatory bowel disease. La­boratory Diagnostics. 2001;40.

Natalie E, Roy A. Sherwood Walsham Fecal cal­protectin in inflammatory bowel disease. Clin Exp Gas­troenterol. 2016;9:21-29.

Faecal calprotectin diagnostic tests for inflam­matory diseases of the bowel / National Institute for Health and Clinical Excellence. NICE diagnostic gui­deline 11.LondonUK; 2013.

Tibble J, Sigthorsson G, Bridger S. Use of sur­rogate markers of inflammation andRomecriteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450-60.

Tibble J, Sigthorsson G, Bridger S. Surrogate mar­kers of intestinal inflammation are predictive of re­lapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.

##submission.downloads##

Як цитувати

1.
Fedorova NS. New aspects of non-invasive diagnosis of intestinal pathology. Med. perspekt. [інтернет]. 04, Травень 2018 [цит. за 20, Грудень 2024];23(1(part2):66-9. доступний у: https://journals.uran.ua/index.php/2307-0404/article/view/126948

Номер

Розділ

КЛІНІЧНА МЕДИЦИНА